XERIS BIOPHARMA HOLDINGS, INC. (XERS) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $9.34M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $4.98M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $9.34M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $9.34M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $4.98M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $4.98M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 421.64M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 9.34M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | 4.98M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 12.72M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $4.98M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $36.85M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.34M | (m) | $4.98M | (m) | $421.64M | (m) | (m) | (m) | $12.72M | (m) |
| 2026-03-31 | (m) | $11.47M | (m) | $4.35M | (m) | $379.00M | (m) | (m) | (m) | $8.13M | (m) |
| 2025-12-31 | (m) | $3.08M | (m) | $4.89M | (m) | $369.84M | (m) | (m) | (m) | $8.40M | (m) |
| 2025-09-30 | (m) | $6.53M | (m) | $2.65M | (m) | $371.05M | (m) | (m) | (m) | $3.39M | (m) |
| 2025-06-30 | (m) | $9.46M | (m) | $1.63M | (m) | $353.99M | (m) | (m) | (m) | $7.75M | (m) |
| 2025-03-31 | (m) | $6.35M | (m) | $156.00K | (m) | $350.58M | (m) | (m) | (m) | $4.83M | (m) |
| 2024-12-31 | (m) | $2.29M | (m) | $1.09M | (m) | $352.68M | (m) | (m) | (m) | $1.97M | (m) |
| 2024-09-30 | (m) | $7.45M | (m) | $678.00K | (m) | $349.43M | (m) | (m) | (m) | $8.55M | (m) |
| 2024-06-30 | (m) | $5.80M | (m) | $997.00K | (m) | $351.02M | (m) | (m) | (m) | $7.71M | (m) |
| 2024-03-31 | (m) | $7.09M | (m) | $801.00K | (m) | $345.79M | (m) | (m) | (m) | $6.06M | (m) |
| 2023-12-31 | (m) | $11.56M | (m) | $1.17M | (m) | $329.38M | (m) | (m) | (m) | $4.85M | (m) |
| 2023-09-30 | (m) | $12.08M | (m) | $1.12M | (m) | $323.92M | (m) | (m) | (m) | $3.70M | (m) |
| 2023-06-30 | (m) | $11.62M | (m) | $1.72M | (m) | $315.14M | (m) | (m) | (m) | $2.65M | (m) |
| 2023-03-31 | (m) | $11.98M | (m) | $2.76M | (m) | $291.31M | (m) | (m) | (m) | $31.00K | (m) |
| 2022-12-31 | (m) | $4.61M | (m) | $2.66M | (m) | $299.33M | (m) | (m) | (m) | $31.00K | (m) |
| 2022-09-30 | (m) | $3.92M | (m) | $337.00K | (m) | $247.98M | (m) | (m) | (m) | $311.00K | (m) |
| 2022-06-30 | (m) | $6.63M | (m) | $916.00K | (m) | $244.67M | (m) | (m) | (m) | $848.00K | (m) |
| 2022-03-31 | (m) | $11.09M | (m) | $619.00K | (m) | $241.17M | (m) | (m) | (m) | $214.00K | (m) |
| 2021-12-31 | (m) | $8.92M | (m) | $1.99M | (m) | $209.13M | (m) | (m) | (m) | $1.68M | (m) |
| 2021-09-30 | (m) | $4.29M | (m) | $95.00K | (m) | $133.72M | (m) | (m) | (m) | $1.90M | (m) |
| 2020-12-31 | (m) | $3.12M | (m) | $322.00K | (m) | $125.39M | (m) | (m) | (m) | $3.53M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |